共 17 条
[3]
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
[J].
ARTHRITIS AND RHEUMATISM,
2009, 60 (08)
:2272-2283
[5]
The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis:: Results from a longitudinal, observational, multicenter study
[J].
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH,
2008, 59 (02)
:234-240
[6]
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
[J].
ARTHRITIS AND RHEUMATISM,
2008, 58 (11)
:3402-3412
[7]
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
[J].
ARTHRITIS AND RHEUMATISM,
2009, 60 (04)
:976-986
[8]
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
[J].
ANNALS OF THE RHEUMATIC DISEASES,
2015, 74 (03)
:538-546
[9]
Kay J, 2009, CORE EVID, V4, P159